A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: A pilot study

Biomarkers

Volumn 18, Issue 6, 2013, Pages 502-508

  Greenberg, Eyal ^a,b   Besser, Michal J ^a,b   Ben Ami, Eytan ^a   Shapira Frommer, Ronnie ^a   Itzhaki, Orit ^a   Zikich, Dragoslav ^a   Levy, Daphna ^a   Kubi, Adva ^a   Eyal, Eran ^c   Onn, Amir ^a   Cohen, Yehudit ^a   Barshack, Iris ^a   Schachter, Jacob ^a   Markel, Gal ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Cancer Research Center   (Israel)

Author keywords

Biomarkers; circulating microRNAs; diagnostic; melanoma; serum

Indexed keywords

MICRORNA; MIRNA 29C; MIRNA 324 3P; OLIGONUCLEOTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; PILOT STUDY; POLYMERASE CHAIN REACTION; RNA EXTRACTION; SERUM;

HUMANS; MELANOMA; MICRORNAS; NEOPLASM METASTASIS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84885193248     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.816777     Document Type: Article

References (35)

1. Andersen CL, Jensen JL, Orntoft TF. (2004). Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245-50.
2. Andreasen D, Fog JU, Biggs W, et al. (2010). Improved microRNA quantification in total RNA from clinical samples. Methods 50:S6-9.
3. Banfalvi T, Boldizsar M, Gergye M, et al. (2002). Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Pathol Oncol Res 8:183-7.
4. BAR-Eli M. (2011). Searching for the 'melano-miRs': miR-214 drives melanoma metastasis. EMBO J 30:1880-1.
5. Bartel DP. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136:215-33.
6. Calin GA, Croce CM. (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-66.
7. Chim SS, Shing TK, Hung EC, et al. (2008). Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 54: 482-90.
8. Cohen JA, Brecher ME, Bandarenko N. (1998). Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 13:16-19.
9. Cummins DL, Cummins JM, Pantle H, et al. (2006). Cutaneous malignant melanoma. Mayo Clin Proc 81:500-7.
10. Deichmann M, Benner A, Bock M, et al. (1999). S100-Beta, melanomainhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17:1891-6.
11. Deichmann M, Kahle B, Moser K, et al. (2004). Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91:699-702.
12. Gallo A, Tandon M, Alevizos I, Illei GG. (2012). The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 7:e30679.
13. Garzon R, Calin GA, Croce CM. (2009). MicroRNAs in cancer. Annu Rev Med 60:167-79.
14. Gloster JR HM, Brodland DG. (1996). The epidemiology of skin cancer. Dermatol Surg 22:217-26.
15. Greenberg E, Hershkovitz L, Itzhaki O, et al. (2011a). Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6:e18936.
16. Greenberg E, Rechavi G, Amariglio N, et al. (2011b). Mutagen-specific mutation signature determines global microRNA binding. PLoS One 6:e27400.
17. Howlader N, Noone AM, Krapcho M, et al. (2011). SEER Cancer Statistics Review, 1975-2008. National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975-2008/
18. Hu Z, Dong J, Wang LE, et al. (2012). Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33:828-34.
19. Hunter MP, Ismail N, Zhang X, et al. (2008). Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694.
20. Ikuta Y, Nakatsura T, Kageshita T, et al. (2005). Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res 11:8079-88.
21. Ivanov SV, Goparaju CM, Lopez P, et al. (2010). Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 285:22809-17.
22. Kanemaru H, Fukushima S, Yamashita J, et al. (2011). The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 61:187-93.
23. Lee WR, Giantonio B, Hanks GE. (1994). Prostate cancer. Curr Probl Cancer 18:295-357.
24. Lim PK, Bliss SA, Patel SA, et al. (2011). Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 71:1550-60.
25. Ma L, Weinberg RA. (2008). MicroRNAs in malignant progression. Cell Cycle 7:570-2.
26. Miller AJ, Mihm JR MC. (2006). Melanoma. N Engl J Med 355: 51-65.
27. Mitchell PS, Parkin RK, Kroh EM, et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513-18.
28. Molina R, Navarro J, Filella X, et al. (2002). S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 23:39-44.
29. Morimura R, Komatsu S, Ichikawa D, et al. (2011). Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 105:1733-40.
30. Mouawad R, Spano JP, Khayat D. (2010). Old and new serological biomarkers in melanoma: where we are in 2009. Melanoma Res 20: 67-76.
31. Nguyen T, Kuo C, Nicholl MB, et al. (2011). Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6: 388-94.
32. Valastyan S, Reinhardt F, Benaich N, et al. (2009). A pleiotropically acting microrna, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-46.
33. Vandesompele J, De Preter K, Pattyn F, et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3, RESEARCH0034 (1-12).
34. Wang LG, Gu J. (2011). Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 36:e61-7.
35. Wulfken LM, Moritz R, Ohlmann C, et al. (2011). MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6:e25787.